Interaction Checker

Interaksi Benralizumab

Benralizumab (Fasenra) memiliki 23 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 0 mayor, 23 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi moderat (23)

  • Azelastin dan flutikasonantihistaminModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • BetametasonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • BudesonidkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • DesonidkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • HalobetasolkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • KlobetasolkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • MometasonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • PrednisolonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidModerat

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

Periksa Benralizumab terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.